• Naturo Group signs contract with BC Wildfire Services Division; will provide special bottled water to over 1,100 firefighters across British Columbia.
• TRACE-branded natural 7.7ph alkaline spring water is sourced directly the source in British Columbia, the very land the firefighters protect.
• BevCanna’s TRACE product line features unique, ancient minerals that offer a broad range of wellness properties including cognitive performance, immune function and gut health.

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) has announced that its wholly owned subsidiary Naturo Group has been selected to manufacture and supply a special, limited-edition run of its TRACE-branded, alkaline spring water to the Wildfire Services Division of the British Columbia Ministry of Forests, Lands, Natural Resource Operations and Rural Development (https://ibn.fm/Mvduv). The division is globally renowned for its wildfire management and employs 1,100 Type 1 firefighters who respond to nearly 1,600 wildfires annually throughout British Columbia. “We’re pleased that we’ve been awarded the contract with BC Wildfire Services,” said BevCanna president Melise Panetta. “We are proud to be providing the firefighters with a special edition of our TRACE-branded natural 7.7ph alkaline spring water, sourced directly from our proprietary BC interior aquifer — the very land and forest that they work so hard to keep safe.” The government supply agreement calls for a limited-edition run of bottled water from BevCanna’s own alkaline spring water source, where the natural, slow filtration of pristine backcountry rain and melted snow through layers of rock and stone create a clean taste experience. The company’s TRACE-branded, mineralized water contains essential trace minerals that help combat illness and disease associated with trace mineral deficiency (https://ibn.fm/O4j57). The special-run bottles are manufactured in the company’s world-class, 40,000-square-foot, HACCP-certified manufacturing facility, which can produce up to 210 million bottles a year. In addition, these memorable water bottles bear a unique label with a personalized message to BC Wildfire Service personnel: Thanks For Being Our BadA** Hero. “We’ve already begun production and delivery to the firefighters,” said Panetta, who noted that the B.C. Ministry of Forests, Lands, Natural Resource Operations and Rural Development is responsible for the stewardship of provincial Crown land and ensures the sustainable management of forest, wildlife, water and other land-based resources. “We think that it’s very fitting that these heroes will be kept hydrated with BC’s own TRACE-branded water,” she said. In addition, the company’s scalable and flexible manufacturing process provides white-label solutions for third-party companies looking to enter this promising space with the highest-quality products available. A manufacturer of traditional and cannabis-infused beverage brands, the company is serving a growing roster of white-label clients. For more information on BevCanna, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Avricore Health has announced that it is ready to roll out its HealthTab rapid disease testing system in pharmacies across Canada
• The rapid disease testing system comprises two key components, Avricore’s web-based HealthTab and Abbott’s Affinion 2 multi-assay analyzer
• The global point-of-care diagnostics market was valued at $34.49 billion in 2020 and is expected to continue growing and reach $81.37 billion by 2028

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), an innovator in pharmacy services focused on the acquisition and development of early-stage technology aimed to move pharmacies forward, is set to roll out its proprietary HealthTab rapid disease testing system in pharmacies across Canada. The rollout comes shortly after the company put its health screening system into 12 Shoppers Drug Mart stores located in the Greater Toronto area, as well as several independent pharmacies in Ontario and British Columbia (https://ibn.fm/B70bn). “This adds a new dimension to the pharmacy practice. By providing this kind of service in a community pharmacy setting, we lower barriers to access to diagnostic information that’s often life-saving and outcome-improving,” Hector Bremner, CEO of Avricore, said. “Ultimately, we’re democratizing access to diagnosis while addressing the needs of pharmacists as they look to getting into more clinical services.” Avricore’s screening process is built upon two key components — HealthTab and Affinion 2. HealthTab is Avricore’s web-based platform. It provides a console-accessible interface where patients can create an account and choose their tests, allowing pharmacists to review and monitor patient information. The Affinion 2 multi-assay analyzer, created by Abbott Laboratories, provides point-of-care patient testing. Once the patient has registered and chosen a test, a pharmacist extracts a small amount of blood through a finger stick. The blood is then collected into a reagent disc and inserted into the Affinion 2. The results are ready in approximately 15 minutes. They are presented in a dashboard format that can be viewed from a computer, mobile device, or printed at the pharmacy. The information integrates easily into pharmacy EMR systems. The screening system can measure up to 21 health markers and currently offers diabetes and cardiovascular disease testing. Depending on the factors, analyzer and number of testing instruments, pharmacies pay between $300 and $500 a month for the system plus the per-test cost between $15 to $40 to cover the single-use test cartridges. Recently, Bremner sat down and spoke with Paul Benwell & Associates (“PBA”) for the “PBA à Noon” podcast, discussing HealthTab and the rapid diagnostic testing services (https://ibn.fm/lRecb). He highlighted the uniqueness of the company’s overall business structure — taking existing technology, bundling it together, and re-introducing it as an innovative service that people want and need. Through HealthTab, data connections are created to interlock the pharmacies, patients and medical doctors. The ecosystem is created to provide seamless patient care while sharing information with telemedicine or other medical professionals for research for expedited real-time reporting capability. The system can be adapted to provide real-time infectious disease tracking. Avricore’s goals for its rapid testing include expansion into more pharmacies across Canada and entry into the United States and United Kingdom’s markets. The partnerships that Avricore has created with companies like Abbott and the select Shoppers Drug Mart pharmacies place Avricore in a prime position to dominate the point-of-care (“POC”) diagnostics landscape — an expanding market rife with opportunities. According to a Fortune Business Insights report, the global POC diagnostics market was valued at $34.49 billion in 2020 and an estimated $43.49 billion in 2021 (https://ibn.fm/wWQSV). The market is expected to continue expanding and reach $81.37 billion in 2028, growing at a CAGR of 9.4% during the forecast period. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Flora Growth Corp recently received coverage from Argus Research, which gives the company’s stock a fair value estimate of $7.50 against the $3.24 recorded July 20
• Argus also projects that Flora’s revenue would increase to $9 million in 2021 and $31 million in 2022, up from $0.1 million reported in 2020
• Flora received a boost in its operations when Colombia’s president accepted and signed reforms to the existing cannabis legislation
• The updated law allows for the manufacture, sale and export of psychoactive (high-THC) cannabinoid ingestible and medical products and removes marketing limitations on cannabis products in Colombia
• Flora is also planning to relocate its headquarters to Miami by Q1 2022

Founded in 2019 and leveraging low-cost cannabis cultivation, an expansive brand and product portfolio, and a strategic global distribution platform, Flora Growth Corp. (NASDAQ: FLGC), an internationally focused cannabis consumer packaged goods company, was featured in a recently released equity research report by Argus Research Company (https://ibn.fm/5mNd1). Argus believes Flora is attractively valued relative to its peers based on its low-cost structure, robust brand portfolio and growing worldwide distribution. It further offers its stock a fair value estimate of $7.50 per share, more than 100% above the $3.24 recorded on July 20. The valuation, calculated using the EV/revenue analysis based on the Argus’ projection of Flora’s 2022 revenue of $32 million — up from a reported 0.1 million in 2020 and an estimated $9 million in 2021 — and an assumption that the company will have $30 million in cash, indicates that FLGC is seen as a worthy stock to follow and perhaps invest in. In its earnings and growth analysis, Argus notes that its revenue forecasts for both 2021 and 2022 exclude the impact of recently announced transactions, suggesting that FLGC’s share price could exceed the $7.50 per share fair value estimate. The transactions Argus was alluding to are a signed letter of intent (“LOI”) to acquire 100% of Koch & Gsell, a leading natural Swiss hemp product manufacturer and owner of hemp brand Heimat, for a stock-based consideration of about $22.2 million, and another LOI for an initial equity investment of approximately $2.4 million (€2 million) into Hoshi International, a vertically integrated medical cannabis company. Kock & Gsell boasts a retail network of more than 2,500 stores in Switzerland and can produce more than 40,000 packs of hemp and hemp-tobacco-blended cigarettes per day. Flora views this acquisition as an opportunity to enter the Swiss market and to leverage their proprietary technology by bringing it to other international markets, while Argus believes this transaction will potentially expand FLGC’s revenue. The equity investment in Hoshi aims to strengthen Flora’s European supply chain and offer access to the rapidly growing EU market. Hoshi, which has a finished products facility in Malta and a wholesale processing facility in Portugal, already has distribution agreements in Poland and Germany, while in other European countries the negotiations are still ongoing. “The investment will establish Flora as a preferred strategic supplier for Hoshi and provide it with a European manufacturing presence and the ability to import Colombian-grown flower and derivatives into Europe,” reads the report (https://ibn.fm/oaMml). Notably, the equity investment comes as the Colombian government, through the president, accepted and signed into effect reformed cannabis legislation aimed at augmenting access to cannabis products for Colombians. The revision also allows for the manufacture, sale and export of psychoactive (high-THC) cannabinoid ingestible products, removes marketing limitations on cannabis products in Colombia, and legalizes the sale of CBD medical products (https://ibn.fm/q44v1). For Flora’s Kasa Wholefoods, a company that produces food and beverages, the change is welcome news. With a distribution agreement to supply food products to Tropi, Colombia’s largest food distributor boasting a distribution network of more than 130,000 points across 38 cities, already announced, the legislative update is expected to increase revenue growth and generate even greater sales of its hemp and CBD products than initially anticipated. Moreover, the change bodes well for Flora Lab, FLGC’s derivative manufacturing and R&D center. The revised law also positions Colombia as the leader to supply the international cannabis market, leveraging its favorable climate for cannabis cultivation and its low production cost in certain regions of the country. Flora immediately reacted to the legislative update by signing an LOI with Kiricann, a South Africa-based international distributor with distribution agreements in the EU and Germany, to supply raw cannabis materials (dried flower) and its derivatives. Flora expects to sign more of these agreements in the near future as the global cannabis market starts taking note of Colombia’s high-quality cannabis and low-cost production. Located near the equator, Flora’s Cosechemos cultivation facility enjoys 12.8 hours of daily sunlight throughout the year, translating to an average daily temperature of 65°F. Additionally, the Bucaramanga region experiences consistent three mph wind that reduces instances of harmful, wind-borne pathogens and pollens. Additionally, the region’s organic nutrient-rich soil permits high-density planting and is some of the most fertile soil in the world. Flora also has access to highly skilled and affordable labor at only 10% of the cost of hiring such a workforce in the United States. Flora’s cultivation property combines all these advantages with additional benefits exclusive to its expansive farm — Cosechemos is licensed to grow cannabis on 247 acres. These unique benefits include the presence of six natural spring water deposits within the sizeable facility, as well as a $10/acre long-term monthly lease. The overall result is the ability to cultivate both high-THC and high-CBD cannabis at a production cost of $0.06 per gram, which is 60% lower than its closest Colombian competitor’s reported cost of $0.15. In comparison, North America-based cannabis producers average a production cost of $1.89 per gram (https://ibn.fm/F0Ri). Elsewhere, Flora also announced its plans to relocate its headquarters to Miami, specifically in Florida’s Brickell financial district, by Q1 2022 (https://ibn.fm/ZnjnE). This announcement follows an exhaustive review process guided by the company’s focus on creating global growth opportunities. According to Flora Growth President and CEO Luis Merchan, Miami satisfied the following requirements: travel & logistics (including time zone), business climate (state corporate tax rate and receptiveness to the cannabis industry), and personal life factors (including talent pool and cost-of leaving). For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• InMed announced a non-binding letter of intent to acquire BayMedica Inc.
• The move is designed to grow InMed’s market presence and strengthen its operations
• The two companies have had a reciprocal research collaboration that dates back to November 2020
• InMed looks to capitalize on the growing cannabinoid industry that is projected to grow at a CAGR of 21.2% from 2021 to 2028

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company committed to developing cannabinoid-based pharmaceutical drug candidates. It also manufactures technologies for pharmaceutical-grade rare cannabinoids. It is known for creating a pipeline of cannabinoid-based pharmaceutical drug candidates to treat various diseases with high unmet medical needs. In a move to grow its market presence and strengthen its operations, the company announced that it had entered into a non-binding letter of intent (“LOI”) to acquire BayMedica Inc. (https://ibn.fm/WJSW5). This announcement followed the two parties’ reciprocal Research Collaboration Agreement back in November 2020, which saw them collaborate on several projects since (https://ibn.fm/WJSW5). The agreement allowed BayMedica to assess particular elements of InMed’s proprietary IntegraSyn(TM) approach in producing cannabinoids. In addition, InMed began a preclinical investigation of different compounds selected from BayMedica’s extensive library of proprietary cannabinoid analogs, designed to be developed to treat human diseases. While making the announcement, Eric A. Adams, the president and chief executive officer (“CEO”) of InMed, noted: “We are very excited about the prospect of continuing to work with BayMedica and the potential to build a leading rare cannabinoid company together (https://ibn.fm/WJSW5).” He further noted that: “Since commencing our collaboration in November last year, it has become apparent that our complementary business models and capabilities have the potential to provide a platform to expedite the growth of both companies and provide the flexibility of multiple processes for the manufacturing of rare cannabinoids.” The acquisition is intended to turn InMed into a powerful cannabinoid manufacturing company. With the company’s IntegraSyn(TM) pharmaceutical-grade manufacturing process, along with BayMedica’s rare cannabinoid manufacturing and ongoing revenue generation, Mr. Adams reckons that the company’s overall value proposition to customers would increase significantly, all while allowing the company to position itself at the forefront of the growing rare cannabinoid sector (https://ibn.fm/T8sD8). BayMedica is a biotechnology company that utilizes its expertise in synthetic biology and pharmaceutical chemistry to develop scalable, efficient and proprietary manufacturing approaches (https://ibn.fm/2068U). With this, it is known to produce regulatory-compliant, high-quality rare cannabinoids designed for the consumer market. Currently, BayMedica is commercializing the rare cannabinoid cannabichromene (“CBC”) as a business-to-business (“B2B”) supplier to distributors and manufacturers who are providing it in the health and wellness sector. The company is targeting additional rare cannabinoid launches for 2022. InMed is committed to becoming a leader in the cannabinoid sector. This move to acquire BayMedica confirms its ambition, along with the successful collaboration that the two companies have had so far. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Brain Scientific poised to disrupt neurology market with two new FDA-cleared patented products that provide cost-effective brain imaging in any setting
• Current global market for EEG devices estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026

With a focus on developing innovative and proprietary medical devices and software, Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with two new FDA-cleared products that provide next-generation solutions to the neurology market. Already patented in the United States, China and Europe, the company’s first commercialized devices — the NeuroCap(TM) and NeuroEEG(TM) — are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. The NeuroCap is a disposable pre-gelled EEG headset that features 22 electrodes and 19 active EEG channels that all adhere to the international 10-20 system. Cleared by the FDA in 2018, the headset can be used for recording EEGs in nearly any setting, including neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. Intended for prescription use, the NeuroEEG is a compact, portable and cost-effective FDA-cleared, clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity for patients of all ages. Both the NeuroEEG and NeuroCap are delivered by MemoryMD Inc., the predecessor and now wholly owned subsidiary of Brain Scientific. Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices. The second, ongoing phase currently focuses on the creation of cloud-based, secure infrastructure to transmit patient data between patients and neurologists. The final and third phase — scheduled for 2021-2023 — aims to focus on the use of AI to facilitate diagnostic analysis and increase the consistency, efficiency, consistency and accuracy of imaging by neurology specialists. Brain Scientific plans on expanding the vision for telemedicine in neurology with an aim to address the current acute neurologist shortfall throughout the U.S. The current global market for EEG devices is estimated at $956.1 million with an expected CAGR of 8.7% from 2019 to 2026 and is expected to reach $1.6 billion by 2026 (https://ibn.fm/Ys8Qi). With its current marketing strategy and development pipelines, BRSF’s management projects significant market penetration in addition to opportunities to collaborate with other businesses — such as EEG manufacturers — that could package Brain Scientific’s solutions with their products and effectively expand the company’s addressable target market. Headquartered in New York, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. were founded in 2015 and went public in 2018. With a focus on developing innovative medical devices and software that disrupt the brain diagnostics market, Brain Scientific is poised to take center stage with solutions that enable medical professionals to cost-effectively diagnose patients with consistency, efficiency and accuracy in virtually any setting. For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• The updated Fan Pass platform features a slew of upgrades including an updated web design and an enhanced user interface/user experience
• The monthly subscription for fans to access the Fan Pass platform is less than a digital download, only $2.99 per month for an All-Access VIP experience
• The company plans to add NFTs to its offering and has a signed Letter of Intent with Santo Blockchain Labs and Santo Mining Corp.
• Fan Pass will continue to monetize livestream events, merchandise and fan subscribers — increasing revenue opportunities for the artists who sign up for the platform

Mobile technology and entertainment company Friendable (OTC: FDBL) released an updated version of its Fan Pass artist livestreaming platform to the app stores on July 24, 2021, exactly on the one-year anniversary of the platform. The corporate milestone includes the delivery of version 2.0 of the platform, making it available on Google Play and the Apple Store. The new version offers an all-new UI/UX experience, updated feature sets for the artists and fans, and accelerates the onboarding process and dashboard features. Version 2.0 also includes an updated and refreshed web design. “Our talented development team worked hard to release v2.0 on the anniversary of our original launch. We believe there are more good things to come as artists currently using our platform discover how we’ve improved their ability to monetize livestream events, merchandise and fan subscribers,” Friendable CEO Robert A. Rositano Jr. said, commenting on the release (https://ibn.fm/CVE2I). “We expect the new features to also reach artists and fans who have not yet experienced our exciting app as we continue to rapidly meet the demands of our growing userbase.” The Fan Pass team is available to help guide artists through the complex process of making a name for themselves. They can do this without the complications and legal hurdles that are present when working with a record label. By leveraging the now available Pro Services, artists are able to build their brand, attract more fans and earn income as a musician with quality artist logo graphics and merchandise designs. Pro Services are easily navigated, with any artist interested being required to first fill out a form, which contains a short survey. Next, designers create a few designs based on the artist’s inspiration and send them the drafts for approval. Once approved, the graphics are delivered to the artist. Artists can get started by visiting https://proservices.fanpasslive.com. Pricing begins at $45 for basic social ad designs to promote the next three artist events. Fans can access their favorite artists on the platform by paying a monthly fee ($2.99), which costs less than a digital download. The All-Access VIP experience provides fans with access to:

• Live music and online concerts
• Backstage meetups — before, during and after live streams
• Livestreams and studio sessions
• Behind-the-scenes footage of music videos and photoshoots
• Special interviews and one-on-one videos
• Streams that highlight the day in the life of the artist

Fans have access to browse upcoming events, shop merch, search by genre, and interact with other fans and artists. Fans can view notifications and discussions while watching their favorite artists in one spot. Above all else, fans can feel good supporting the independent artists they love. As part of its strategy to continue to increase revenue-generating opportunities for its members, Fan Pass plans to add non-fungible tokens (“NFTs”) to its offering. NFTs are a unit of data that is stored on a digital ledger (blockchain) and certifies that a digital asset is unique and not interchangeable. NFTs are representative of items such as photos, videos, audio, and other types of digital-based files. Friendable has already signed a Letter of Intent (“LOI”) with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) to develop global entertainment and music artist-driven NFTs, as well as a dedicated “Fanpasscrypto” marketplace. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• TAAT flagship product also earned distinction as second runner-up to Best in Show.
• “Awards are excellent indicator of how product is received by an audience of buyers keen to embrace concepts such as ours,” says CEO.
• Trade shows are key pieces in company’s strategic plan to grow presence, awareness in the tobacco industry.

In its first convention appearance since launching in October of last year, TAAT(TM) Global Alternatives’ (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) flagship product was named Best New Product and earned the second-highest honor as Best in Show. The company began a round of trade shows by participating at the HQ Event, a business-to-business (“B2B”) trade show for specialty lifestyle vendors, including purveyors of vaping and combustible smoking products, held in Las Vegas. “Alternatives to tobacco cigarettes such as vaping and herbal cigarettes have long been popular product categories at trade shows as demand persists from smokers aged 21+ for better choices,” stated TAAT CEO Setti Coscarella. “Now that in-person events such as B2B trade shows are back in operation, we are excited to be able to exhibit TAAT(TM) to buyers from around the globe who are attending shows such as the HQ Event and CHAMPS. I believe the two awards TAAT won at the HQ Event this week are an excellent indicator of how our product is received by an audience of buyers keen to embrace concepts such as ours.” The TAAT booth at the two-day HQ Event featured the complete line of TAAT product in Original, Smooth and Menthol; the exhibit saw a steady stream of interested conference attendees, all eager to learn more about TAAT’s game-changing tobacco-free, nicotine-free alternative to traditional cigarettes. Throughout the show, which was held July 21–22, 2021, company reps answered questions, provided information and built an invaluable network of wholesale and retail buyers from around the country. These trade shows are key pieces in the company’s strategic plan to grow its presence in the tobacco industry. TAAT executives plan to continue to exhibit at key conventions and trade shows as the company focuses on bringing TAAT to the $814 billion global tobacco industry. TAAT’s Beyond Tobacco(TM) cigarettes provide an alternative option unlike any other — a smooth, satisfying experience that mirrors traditional smoking. With TAAT, users can enjoy a tobacco-like scent and taste along with hand-to-mouth and flicking ashes motions — all without any actual tobacco and nicotine. To learn more about this company, visit www.TryTAAT.com and www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• Team is always looking for ways to support dedicated brand partners in growing their businesses
• New materials include Spanish-language sizzle videos, product-marketing assets and other sales tools
• Company recently announced plans to unveil entire U.S. product line to customers in 21 European countries

Sharing Services Global (OTCQB: SHRG) and its subsidiary The Happy Co. have unveiled new Spanish-language resources to support the growing U.S. Latino market, as well as other Spanish-speaking countries around the globe (https://ibn.fm/jgET7). The Happy Co. is a leading producer and distributor of nootropic, functional beverage products with a focus on health and wellness. “Our team is always looking for new ways to better support our dedicated brand partners in growing their businesses,”said Bo Short, CEO of The Happy Co., formerly Elevacity International Holdings LLC. “While this is just a first step, it is one that puts us on a good path to empowering our field to build globally.We’re excited to share these resources and continue identifying new ways to support our community of entrepreneurs in achieving their business goals.” The new materials include Spanish-language sizzle videos, product-marketing assets and other sales tools to support Latino brand partners who are working to grow their businesses with The Happy Co. Recently, the company announced several growth initiatives, including its plan to unveil its entire U.S. product line on an NFR basis to customers in 21 European countries. The Happy Co. launched in February 2021 with an established foundation of distinctive nootropic products. The company offers functional beverages, capsules, patches and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin, and make you look, feel and perform like a younger person. The products are nootropics, or nutraceutical formulations derived from food sources that provide health benefits above and beyond basic nutritional value. Although the company does produce superior products, its mission is to provide its business partners and consumers with much more than that. “We are a lifestyle and a dose of happy,” the company’s slogan proclaims. A publicly traded company specializing in the direct-sales sector, Sharing Services Global Corporation is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy
• Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies
• Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls
• The complete results of the study will be produced as sample and data analyses work are completed
• Lexaria is already under way on a second study that examines the efficacy of DehydraTECH-enabled CBD in repeat dosing, and the company anticipates positive outcomes based on the partial results of the first study that were just released

Ongoing clinical studies of the DehydraTECH platform’s ability to render therapeutic drugs into a powder or liquid form that increases their ability to be rapidly absorbed by the body without adverse changes to the original substances have yielded important new findings on the blood pressure and heart disease fronts. Bioavailability technology innovator Lexaria Bioscience (NASDAQ: LEXX)  announced partial results from its human clinical study HYPER-H21-1 on July 29, which is evaluating cannabidiol (“CBD”) processed with DehydraTECH, to determine its potential against hypertension. The initial results show DehydraTECH-enabled CBD produced a reduction in blood pressure in both male and female volunteers and was most pronounced in comparison against generic CBD controls during the first 10 to 50 minutes after administration, adding to Lexaria’s evidences that DehydraTECH-enabled drugs take effect more rapidly than generic controls, according to the company’s news release (https://ibn.fm/ps9d7). “We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers,” Lexaria CEO Chris Bunka stated in the news release. According to the U.S. Centers for Disease Control and Prevention (“CDC”), heart disease is the leading cause of death for men, women and most classifications of people divided by racial and ethnic groups in the United States. One in every four deaths is attributed to heart disease alone, and the costs of related health care, medicines and lost job productivity exceed $200 billion each year (https://ibn.fm/obXUx). Multiple studies involving people with high, average and below-average levels of blood pressure have shown that lowering blood pressure reduces the risk of heart disease and stroke in all of those categories, which is a basis for prescribing blood-pressure-reducing drugs to the population at large based on risk factors of age and prior heart disease events regardless of periodic blood pressure checkup results (https://ibn.fm/C0y58). Blood pressure drugs and related medications have thereby resulted in a multi-billion-dollar industry. Lexaria’s partial results show its greatest comparative reduction from baseline was in systolic pressure, but there were also marked reductions in relative diastolic pressure from baseline and relative mean arterial pressure from baseline against the generic CBD controls. “Other studies of coronary heart disease (‘CHD’) have concluded that ‘lowering systolic pressure by 10 mm Hg or diastolic pressure by 5 mm Hg using any of the main classes of drugs reduced CHD events (fatal and nonfatal) by about a quarter and stroke by about a third, regardless of the presence or absence of vascular disease and of pretreatment BP. Heart failure is also reduced by about 25%,” Lexaria’s news release states. The company also noted that all of the study’s participants tolerated the DehydraTECH-enabled CBD without any serious adverse events or side effects, while some participants who used the concentration-matched, generic CBD control reported unwanted side effects such as gastrointestinal distress including diarrhea. Lexaria will provide an update on this study when sample and data analyses work for are complete. The company is optimistic that the partial results reported thus far are predictive of further enhanced efficacy through repeat dosing being analyzed in its second human clinical hypertension study, HYPER-H21-2, which is already under way (https://ibn.fm/j5sG0). A third planned human clinical hypertension study will be conducted this year once the results of HYPER-H21-1 and HYPER-H21-2 are carefully evaluated. The company also anticipates inflammatory marker assessments may ultimately be applicable to its research in the antiviral therapeutics space for potentially treating COVID-19 and other common pro-inflammatory conditions. Lexaria has already successfully demonstrated DehydraTECH usefulness in that area (https://ibn.fm/N6H6u). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1
• The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screenings
• The global cancer diagnostics market size is expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening, detection, and cancer treatment, announced that it experienced strong growth in test volume in the first half of 2021. The total number of paid customers and testing volume increased almost 110% compared to the same period in 2020. Additionally, Q2 saw the total of paid tests and paid cancer tests increase by approximately 280% and 270%, respectively. The company has also seen growth in the new test products that it had launched in 2020 (https://ibn.fm/Josef). AnPac is a highly innovative company and an early thought leader, developing multi-cancer screening technology, which has gained significant acceptance. The company’s approach, Cancer Differentiation Analysis (“CDA”), uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments within the body before the tumors form. The CDA is powered by a database of over 200,000 samples and cases, serving as a new way to approach disease and cancer screenings. The device uses an integrated system of sensors to detect biophysical signals at the cellular, protein, and molecular level. CDA uses a proprietary algorithm to synthesize data, generating a personalized risk assessment for evaluating patients. “We are incredibly pleased with our strong test volume growth in the first half of 2021. We believe that our cost-effective, multi-cancer, high-performance cancer test packages are gaining increased customer and market acceptance,” AnPac CEO, Dr. Chris Yu, said while commenting on the testing volume increase. “We will work hard to continue commercialization in China and to achieve LDT approval in the U.S., allowing us to further accelerate our revenue growth.” With the significant market opportunities, increased customer and market acceptance, and given that historically the company has seen stronger test volume in the second half of the year compared to the year prior, AnPac expects the strong growth standard to continue through the remaining part of the year. The company has already made notable contributions to the cancer screening field. Compared to its industry peers, AnPac has 142 issued patents as of March 2021, whereas GRAIL, Inc. has 80 patents, and Thrive Earlier Detection Corp. only has 1 filed patent. As an early thought leader, the patent applications and IP for the company started in the early 2010s. By 2014, AnPac had already announced that the cancer detection product it developed was capable of screening 16 types of cancer, which was earlier than anyone else. These achievements help position AnPac as a leading entity on the global cancer diagnostics market, an expanding market expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period. This growth can be attributed to the innovation of new products and the rising urgency for early cancer detection. The rise in cancer incidents is demanding better screening and modalities used for monitoring disease progression (https://ibn.fm/3Vylk). Through its CDA technology, AnPac aims to tackle multiple aspects and challenges of the industry, including innovation, detection, identity, results, and biophysical properties. Through the test samples, CDA has been able to diagnose and identify pre- and early-stage cancers in patients that were previously diagnosed as cancer-free through traditional methods. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC